Incyte stock price target raised to $109 by BofA on strong Jakafi sales
PositiveFinancial Markets

Incyte's stock price target has been raised to $109 by Bank of America, reflecting strong sales of its drug Jakafi. This increase is significant as it highlights the growing confidence in Incyte's performance and the effectiveness of Jakafi in treating certain conditions. Investors are likely to view this as a positive sign for the company's future prospects, especially in a competitive pharmaceutical market.
— Curated by the World Pulse Now AI Editorial System








